PROGRAM CO-CHAIRS
Jessica R. Allegretti, MD, MPH, FACG, AGAF
Director, Crohn’s and Colitis Center
Director of Clinical Research
Director, Fecal Microbiota Transplant Program
Division of Gastroenterology,
Hepatology and Endoscopy
Brigham and Women’s Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Christina Ha, MD, FACG, AGAF
Director, Inflammatory Bowel Disease Section
Associate Professor of Medicine
Mayo Clinic Arizona
Scottsdale, Arizona
PROGRAM OVERVIEW
The enduring activity aims to enhance health care professionals’ capacity to utilize evidence regarding the long-term effectiveness of anti-IL-23p19 biologics in making clinical decisions for ulcerative colitis (UC) and Crohn’s disease (CD). It will focus on the integration of objective measures, such as endoscopy, histology, and biomarkers, into the assessment of long-term efficacy. Additionally, the symposium will facilitate the analysis of the comparative value of corticosteroid-free remission, promoting its application in shared decision-making.
LEARNING OBJECTIVES
- Apply evidence on the long-term efficacy of anti-IL-23p19 biologics in clinical decision-making for ulcerative colitis (UC) and Crohn’s disease (CD).
- Integrate objective makers, including endoscopy, histology, and biomarkers, into long-term efficacy assessment.
- Analyze the comparative value of corticosteroid-free remission and apply it to shared decision-making, ensuring that treatment goals are focused on patient-centered outcomes and targets for disease modification.
TARGET AUDIENCE
This activity is designed to meet the needs of health care professionals (HCPs) involved in the care of patients with inflammatory bowel disease (IBD) such as gastroenterologists, as well as GI physician associates (PAs) and GI nurse practitioners (NPs).
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
AAPA CREDIT DESIGNATION STATEMENT – Enduring Materials
Med Learning Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until February 17th, 2027 . PAs should only claim credit commensurate with the extent of their participation.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIP(S)
Dr Allegretti discloses her work as a consultant for Janssen, Pfizer, AbbVie, Vedanta Biosciences, Genentech, Seres Therapeutics, Ferring Pharmaceuticals, GSK, Merck, Bristol Myers Squibb, Roivant, Celltrion, TRX Bio, Xencor, Shattuck Labs, Metagen Therapeutics, and Curogen and as a speaker for AbbVie and Janssen
Dr Ha discloses her work as a consultant/advisory board member for AbbVie, Bristol Myers Squibb, Celltrion, Johnson & Johnson, Lilly, Merck, and Takeda Pharmaceuticals with educational grant support from AbbVie, Johnson & Johnson, Celltrion, Lilly, and Takeda; she has served on the steering committee for IBD Education Group and MILESTONE IBD
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, Senior VP of Operations for Med Learning Group, has nothing to disclose.
- Arpan Patel, MD, independent reviewer, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Sharon Windsor Harker, BSc, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity.
In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation.
Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: February 17, 2026
EXPIRATION DATE: February 17, 2027
Copyright © 2026 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
